|Bid||3.4600 x 1800|
|Ask||3.5200 x 800|
|Day's Range||3.4850 - 3.5950|
|52 Week Range||3.3100 - 7.7200|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 23, 2022 - Mar. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do...
Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be sufficient to cover MydCombi NDA resubmission, completion of Phase 3 MicroLine program, and completion of manufacturing facility Company to host conference call and webcast tomorrow, November 11, at 5:00pm ET NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophtha